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Abstract
For septic patients, delaying the initiation of antimicrobial therapy or choosing an inappropriate antibiotic can considerably worsen their
prognosis. This study evaluated the impact of rapid microbial identiﬁcation (RMI) from positive blood cultures on the management of
patients with suspected sepsis. During a 6-month period, RMI by matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS) was performed for all new episodes of bacteraemia. For each patient, the infectious disease specialist was
contacted and questioned about his therapeutic decisions made based on the Gram staining and the RMI. This information was collected to
evaluate the number of RMIs that led to a therapeutic change or to a modiﬁcation of the patient’s general management (e.g. fast removal of
infected catheters). During the study period, 277 new episodes of bacteraemia were recorded. In 71.12% of the cases, MALDI-TOF MS
resulted in a successful RMI (197/277). For adult and paediatric patients, 13.38% (21/157) and 2.50% (1/40) of the RMIs, respectively,
resulted in modiﬁcation of the treatment regimen, according to the survey. In many other cases, the MALDI-TOF MS was a helpful tool for
infectious disease specialists because it conﬁrmed suspected cases of contamination, especially in the paediatric population (15/40 RMIs,
37.50%), or suggested complementary diagnostic testing. This study emphasizes the beneﬁts of RMI from positive blood cultures. Although
the use of this technique represents an extra cost for the laboratory, RMI using MALDI-TOF MS has been implemented in our daily practice.
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Introduction
Sepsis is a major cause of morbidity and mortality in
hospitalized patients. In the USA, 750 000 cases of severe
sepsis occur annually [1]. In Europe, sepsis occurs in more than
35% of the patients in the intensive care unit. More than 50%
of patients who experience septic shock do not survive [2–4].
The management of bacteraemic patients can be improved
by the administration of the appropriate treatment without
delay [5–7]. Molecular techniques allow for rapid microbial
identiﬁcation (RMI) from blood samples but have limitations, in
particular the high cost per analysis and the need for
antimicrobial susceptibility testing [8].
Because it allows the identiﬁcation of microorganisms in a
few minutes instead of the hours required by biochemical
techniques, matrix-assisted laser desorption/ionization time--
of-ﬂight mass spectrometry (MALDI-TOF MS) is a promising
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alternative diagnostic tool [9]. Since its commercialization at
the beginning of the twenty-ﬁrst century, many new strategies
to perform RMI directly from clinical samples have been
evaluated [10–13]. Recently, inexpensive strategies that allow
RMI within 20 min after the blood culture becomes positive
were described [14,15].
Currently, the usefulness of RMI is still debated. Arguments
for RMI state that RMI could lead to the faster adoption of the
appropriate antibiotic regimen and help to identify the cause of
the sepsis if it is unknown. The still limited information
concerning the susceptibility of the microorganisms to
antimicrobials is a weakness of RMI [16,17].
The primary aim of this study was to prospectively evaluate
the theoretical impact of RMI from positive blood cultures on
the clinical management of bacteraemic patients in our
hospitals. The compliance with the recommendations of the
infectious disease specialist (IDS) was also retrospectively
evaluated to determine the real clinical impact of the RMI
technique.
Materials and Methods
Location
The Saint-Pierre University Hospital and the Jules Bordet
Institute are university-afﬁliated medical centres located in
Brussels, Belgium. Saint-Pierre is a public hospital with vast
experience in infectious diseases. Jules Bordet is the only
hospital in Belgium that is completely dedicated to cancer. Both
institutions are served by the same laboratory, which is open
on weekdays from 07.30 until 20.00 h and on Saturday and
Sunday from 08.00 until 16.00 h. Positive blood culture bottles
are analysed during these time periods. During the night,
medical microbiologists and IDSs are on call for emergencies.
Collection of blood cultures and inclusion criteria
From September 2011 to March 2012, the ﬁrst positive blood
culture for each bacteraemic episode in patients from both
hospitals was prospectively enrolled in the study. All positive
cultures for the same patient obtained within 3 days of each
other and presenting the same Gram staining results were
considered as belonging to the same episode. When staphy-
lococcal morphology was observed in the Gram staining, RMI
was always performed to conﬁrm or rule out contamination.
MALDI-TOF MS RMI
The positive blood cultures (Bactec Plus Aerobic and Bactec F
Lytic Anaerobic; Becton Dickinson, Franklin Lakes, NJ, USA)
were prepared and analysed according to a previously
described in-house protocol [14]. The spectra were acquired
on a Microﬂex LT system (Bruker Daltonics, Bremen,
Germany) and subsequently analysed using MALDI BIOTYPER
AUTOMATION CONTROL AND BIOTYPER 3.0 software. At that time,
the database (V3.1.2.0) included 3995 spectra. The analyses
were performed in batches twice daily. The RMIs were
classiﬁed as ‘reliable’ or ‘unreliable’ according to previously
FIG. 1. Design of the prospective analysis.
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TABLE 1. Rapid microbial identiﬁcation (RMI) transmitted to the infectious disease specialist for cultures that showed
Gram-negative bacteria (n = 71)
Patient
no.
Gram
staining RMI Score H Log
Reliable
RMI? T? CIT
RMI/CIT
discrepancy?
From
incubator
removal
to RMI
delay
(min)
From
incubator
removal
to CIT
delay
(min)
204 GNR A. genomospecies 1.473 1 0.157 N WC A. faecalis Y 50 2950
111 GNR A. johnsonii 1.957 6 0.774 Y Y A. johnsonii N 73 3064
90 GNR A. genomospecies 2.035 3 0.651 Y Y A. lowﬁi Ya 50 2975
241 GNR A. lowﬁi 2.003 7 0.818 Y Y Acinetobacter sp. N 151 1479
56 GNR K. sedentariusb 1.118 1 0.113 N WC Anaerobic GNR Y MD MD
97 GNR
Campylobacter
suspected
C. fetus 1.924 7 0.645 Y Y Campylobacter sp. N 101 3336
27 GNR E. cloacae 1.938 4 0.339 Y Y E. cloacae complex N 93 1559
125 GNR E. cloacae 1.888 10 NA Y Y E. cloacae complex N 54 1437
232 GNR E. cloacae 2.026 4 0.21 Y Y E. cloacae complex N 22 1150
262 GNR E. cloacae 2.266 6 0.374 Y Y E. cloacae complex N 104 1579
10 GNR E. coli 2.241 10 NA Y Y E. coli N 65 1683
14 GNR E. coli 2 8 0.275 Y Y E. coli N 21 1369
25 GNR E. coli 2.254 10 NA Y Y E. coli N 92 1558
30 GNR E. coli 1.806 6 0.273 N WC E. coli N 68 1395
38 GNR E. coli 1.979 7 0.492 Y Y E. coli N 47 1098
45 GNR E. coli 2.279 8 0.272 Y Y E. coli N 75 1061
57 GNR E. coli 2.33 10 NA Y Y E. coli N 61 1497
70 GNR E. coli 1.261 8 0.26 Y Y E. coli N 148 1555
95 GNR E. coli 2.073 9 0.574 Y Y E. coli N 58 2970
131 GNR E. coli 2.196 9 0.605 Y Y E. coli N 80 1180
144 GNR E. coli 1.851 10 NA Y Y E. coli N 71 1676
154 GNR E. coli 2.276 8 0.423 Y Y E. coli N 203 1639
155 GNR E. coli 2.291 9 0.578 Y Y E. coli N 167 1544
175 GNR E. coli 1.954 10 NA Y Y E. coli N 97 1555
181 GNR E. coli 2307 9 0.522 Y Y E. coli N 325 1472
213 GNR E. coli 2.085 10 NA Y Y E. coli N 37 1473
214 GNR E. coli 2.139 9 0.548 Y Y E. coli N 34 1161
224 GNR E. coli 2342 10 NA Y Y E. coli N 86 1625
233 GNR E. coli 1.837 10 NA Y Y E. coli N 452 1639
239 GNR E. coli 2.187 6 0.278 Y Y E. coli N 168 1552
243 GNR E. coli 1.888 9 0.493 Y Y E. coli N 15 1788
250 GNR E. coli 2.367 9 0.46 Y Y E. coli N 86 1583
258 GNR E. coli 2.167 10 NA Y Y E. coli N MD MD
263 GNR E. coli 2.192 10 NA Y Y E. coli N 105 1516
264 GNR E. coli 2.292 10 NA Y Y E. coli N 106 1517
273 GNR E. coli 2.153 8 0.413 Y Y E. coli N 206 1595
281 GNR E. coli 1.798 9 0.636 Y Y E. coli N 273 1595
282 GNR E. coli 1.391 6 0.28 N WC E. coli N 274 1596
286 GNR E. coli 2.313 9 0.451 Y Y E. coli N 187 1529
288 GNR E. coli 2.148 8 0.303 Y Y E. coli N 336 1456
296 GNR E. coli 2.314 9 0.361 Y Y E. coli N 257 1516
299 GNR E. coli 2.209 8 0.547 Y Y E. coli N 60 1101
300 GNR E. coli 2.091 8 0.465 Y Y E. coli N 38 1463
255 GNRcc H. inﬂuenzae 2.125 10 NA Y Y H. inﬂuenzae N 95 3062
259 GNRcc H. inﬂuenzae 1.635 10 NA Y Y H. inﬂuenzae N MD MD
109 GNR K. oxytoca 2.27 3 0.365 Y Y K. oxytoca N 73 1553
218 GNR K. oxytoca 2.234 2 0.283 Y Y K. oxytoca N 95 1516
13 GNR K. pneumoniae 1.92 4 0.4 Y Y K. pneumoniae N 65 1691
41 GNR K. pneumoniae 1.903 6 0.435 Y Y K. pneumoniae N 110 1569
58 GNR K. pneumoniae 2.153 4 0.306 Y Y K. pneumoniae N 180 1621
77 GNR K. pneumoniae 1.829 3 0.267 N WC K. pneumoniae N 56 2199
78 GNR K. pneumoniae 1.325 7 0.426 Y Y K. pneumoniae N 55 1648
99 GNR K. pneumoniae 2.239 7 0.411 Y Y K. pneumoniae N 100 1646
112 GNR K. pneumoniae 2.22 6 0.369 Y Y K. pneumoniae N 74 1572
134 GNR K. pneumoniae 2.088 1 0.258 Y Y K. pneumoniae N 136 2075
135 GNR K. pneumoniae 1.786 7 0.362 Y Y K. pneumoniae N 136 1515
168 GNR K. pneumoniae 2.199 5 0.223 Y Y K. pneumoniae N 62 1654
211 GNR K. pneumoniae 2.071 9 0.402 Y Y K. pneumoniae N 43 1209
297 GNR K. pneumoniae 1.932 1 0.237 N WC K. pneumoniae N 39 1030
26 GNR P. aeruginosa 2.178 6 1.06 Y Y P. aeruginosa N 93 1559
85 GNR P. aeruginosa 2.265 6 0.68 Y Y P. aeruginosa N 95 1548
145 GNR P. aeruginosa 2.253 6 0.757 Y Y P. aeruginosa N 181 1923
289 GNR P. agglomerans 1.807 3 0.24 N WC P. agglomerans N 83 4561
153 GNR P. buccae 2.15 6 1.084 Y Y P. buccae N 104 10499
119 GNR P. mirabilis 2.335 9 0.8 Y Y P. mirabilis N 468 1523
67 GNR P. veronii 1.613 1 0.109 N WC Pseudomonas sp. N 200 1323
268 GNR R. ornitholytica 2.508 1 0.39 Y WC R. planticola Ya 154 1507
265 GNR S. maltophilia 1.419 1 0.186 N WC S. maltophilia N 259 1384
55 GNR Salmonella sp. 2.242 9 0.36 Y Y S. paratyphi N 118 1519
190 GNR Salmonella sp. 1.919 10 NA Y Y S. typhimurium N 217 1512
150 GNR Salmonella sp. 2.321 10 NA Y Y Salmonella sp. N 224 1614
CIT: conventional identiﬁcation technique; GNR: Gram-negative rods; GNRcc: Gram-negative rods coccobacilli; H: Homogeneity; T?: Transmission of the RMI to the IDS?; Y: yes,
N: no; WC: with caution; NA: not applicable; MD: missing or incomplete data; A. genomospecies, Acinetobacter genomospecies; A. johnsonii, Acinetobacter johnsonii; A. lowﬁi,
Acinetobacter lowﬁi; A. faecalis, Alcaligenes faecalis; C. fetus, Campylobacter fetus; E. cloacae, Enterobacter cloacae; E. coli, Escherichia coli; H. inﬂuenzae, Haemophilus inﬂuenzae;
K. sedentarius, Kytococcus sedentarius; K. oxytoca, Klebsiella oxytoca; K. pneumoniae, Klebsiella pneumoniae; P. agglomerans, Pantoea agglomerans; P. buccae, Prevotella buccae; P. mirabilis,
Proteus mirabilis; P. aeruginosa, Pseudomonas aeruginosa; P. veronii, Pseudomonas veronii; R. ornithocolytica, Raoultella ornithocolytica; R. planticola, Raoultella planticola; S. maltophilia,
Steonotrophomonas maltophilia; S. paratyphi, Salmonella paratyphi; S. typhimurium, Salmonella typhimurium.
Homogeneity: number of successive matches identical to the ﬁrst one; log: difference between the score of the ﬁrst match and the ﬁrst discrepancy.
aKnown limitations of the MALDI-TOF MS.
bThe medical microbiologist told the IDS that an anaerobic bacterium was suspected (bad MALDI-TOF MS result and anaerobic bottles).
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TABLE 2. Rapid microbial identiﬁcations (RMIs) transmitted to the infectious disease specialist (IDS) for cultures that showed
Gram positive bacteria (n = 107)
Patient
no.
Gram
staining RMI Score H Log
Reliable
RMI? T? CIT
RMI/CIT
discrepancy
From
incubator
removal to
RMI delay
(min)
From
incubator
removal to
CIT delay
(min)
257 GPR B. cereus 1.689 2 0.109 N WC B. cereus N MD MD
157 GPR B. licheniformis 1.891 5 0.802 Y Y Bacillus sp. N 165 1572
141 GPR C. amycolatum 1.387 4 0.234 N WC C. amycolatum N 264 1236
106 GPCc S. pettenkoferi 1.716 2 0.568 Y Y CNS N MD MD
164 GPCc E. canisa 1.204 1 0.126 N WC E. durans Y 183 3034
140 GPCpch E. faecalis 1.912 8 0.763 Y Y E. faecalis N 35 1524
180 GPCpch E. faecalis 1732 8 0.584 Y Y E. faecalis N 54 1519
197 GPCpch E. faecalis 1.673 8 0.565 Y Y E. faecalis N 88 1582
287 GPCpch E. faecalis 2.034 8 0.811 Y Y E. faecalis N 41 1022
156 GPCpch E. faecium 1.955 9 0.892 Y Y E. faecium N 167 1770
272 GPR L. crispatus 1.321 1 0.267 N WC Lactobacillus sp. N 76 4459
88 GPCc M. luteus 1.526 2 0.513 Yb Y Micrococcus sp. N 48 1167
183 GPCc M. luteus 1.391 2 0.512 N WC Micrococcus sp. N 47 1315
184 GPCc K. sedentarius 1.63 1 0.526 Y Y Micrococcus sp. N 144 3006
194 GPCc M. luteus 1.425 1 0.297 N WC Micrococcus sp. N 90 1707
292 GPCc M. luteus 1.798 3 0.499 Y Y Micrococcus sp. N 152 1617
102 GPR Propionibacterium sp. 1.684 7 0.607 Y Y Popionibacterium sp. N 96 4659
35 GPCpch S. agalactiae 2.147 9 0.704 Y Y S. agalactiae N 46 1641
215 GPCpch S. anginosus 1.444 2 0.241 N WC S. anginosus N 94 1540
71 GPCc S. aureus 1.624 8 0.59 Y Y S. aureus N 170 1506
80 GPCc S. aureus 2.099 10 NA Y Y S. aureus N 78 1515
98 GPCc S. aureus 1.854 10 NA Y Y S. aureus N 233 1518
151 GPCc S. aureus 1.45 7 0.352 Yb WC S. aureus N 52 1382
167 GPCc S. aureus 1.817 10 NA Y Y S. aureus N 281 1564
285 GPCc S. aureus 1692 9 0.475 Y Y S. aureus N 274 1596
75 GPCc S. capitis 1.589 4 0.466 Yb WC S. capitis N 596 1507
83 GPCc S. capitis 1.987 5 0.743 Y Y S. capitis N 125 1192
114 GPCc S. capitis 1.813 5 0.59 Y Y S. capitis N MD MD
128 GPCc S. capitis 1.637 2 0.604 Y Y S. capitis N 85 1579
147 GPCc S. capitis 1.597 4 0.474 Y Y S. capitis N 226 1611
148 GPCc S. capitis 1.457 5 0.393 Yb WC S. capitis N 225 1611
277 GPCc S. capitis 1.732 3 0.35 Y Y S. capitis N 77 1457
115 GPCpch S. dysgalactiae 1.824 4 0.188 N WC S. dysgalactiae N 87 1152
3 GPCc S. epidermidis 2 8 0.616 Y Y S. epidermidis N 131 1554
32 GPCc S. epidermidis 1.99 7 0.63 Y Y S. epidermidis N 69 1397
36 GPCc S. epidermidis 1.287 2 0.18 N WC S. epidermidis N 47 1560
59 GPCc S. epidermidis 1.728 7 0.65 Y Y S. epidermidis N 87 1527
64 GPCc S. epidermidis 2.007 8 0.735 Y Y S. epidermidis N 93 1542
76 GPCc S. epidermidis 1.422 4 0.255 N WC S. epidermidis N 172 1555
82 GPCc S. epidermidis 1.885 6 0.719 Y Y S. epidermidis N MD MD
87 GPCc S. epidermidis 1.395 3 0.201 N WC S. epidermidis N 96 1526
89 GPCc S. epidermidis 1.223 4 0.384 N WC S. epidermidis N 534 1482
96 GPCc S. epidermidis 1.653 6 0.651 Y Y S. epidermidis N 65 1492
103 GPCc S. epidermidis 1.88 9 0.844 Y Y S. epidermidis N 95 1601
107 GPCc S. hominisc 1.978 6 0.934 Y Y S. epidermidis Y MD MD
110 GPCc S. epidermidis 1.79 6 0.566 Y Y S. epidermidis N 73 1553
121 GPCc S. epidermidis 1.91 8 0.615 Y Y S. epidermidis N 130 1511
123 GPCc S. epidermidis 1.708 6 0.65 Y Y S. epidermidis N 99 1509
126 GPCc S. epidermidis 1.71 5 0.351 Y Y S. epidermidis N 41 1155
129 GPCc S. epidermidis 1.262 2 0.162 N WC S. epidermidis N 190 1335
133 GPCc S. epidermidis 1.463 1 0.318 Yb WC S. epidermidis N MD MD
136 GPCc S. epidermidis 2.086 7 0.753 Y Y S. epidermidis N MD MD
139 GPCc S. epidermidis 1.779 7 0.618 Y Y S. epidermidis N 36 1525
146 GPCc S. epidermidis 1.865 6 0.658 Y Y S. epidermidis N 150 1387
158 GPCc S. epidermidis 1.601 2 0.505 Y Y S. epidermidis N 143 1176
160 GPCc S. epidermidis 1.72 6 0.457 Y Y S. epidermidis N 244 1324
161 GPCc S. epidermidis 2.187 8 0.966 Y Y S. epidermidis N 127 1545
162 GPCc S. epidermidis 1.357 2 0.059 N WC S. epidermidis N 57 1139
166 GPCc S. epidermidis 2.05 6 0.502 Y Y S. epidermidis N MD MD
186 GPCc S. epidermidis 1.509 2 0.352 Yb WC S. epidermidis N 93 1594
201 GPCc S. epidermidis 1.623 8 0.316 Y Y S. epidermidis N 76 1537
216 GPCc S. epidermidis 1.858 8 0.635 Y Y S. epidermidis N 95 1516
249 GPCc S. epidermidis 1.774 8 0.481 Y Y S. epidermidis N 86 1583
253 GPCc S. epidermidis 1.793 8 0.636 Y Y S. epidermidis N 94 1824
256 GPCc S. epidermidis 1.717 4 0.606 Y Y S. epidermidis N MD MD
260 GPCc S. epidermidis 1.238 1 0.186 N WC S. epidermidis N MD MD
267 GPCc S. epidermidis 1.866 7 0.606 Y Y S. epidermidis N 154 1507
269 GPCc S. epidermidis 1828 8 0.698 Y Y S. epidermidis N 153 1506
271 GPCc S. epidermidis 1.378 4 0.297 N WC S. epidermidis N 77 1559
275 GPCc S. epidermidis 1.606 2 0.17 N WC S. epidermidis N 133 1558
278 GPCc S. epidermidis 1.303 5 0.349 N WC S. epidermidis N 119 1581
306 GPCc S. epidermidis 1.698 5 0.622 Y Y S. epidermidis N MD MD
234 GPCpch S. gallolyticus 1.849 3 0.434 Y Y S. gallolyticus N 174 2066
93 GPCc S. haemolyticus 1.921 7 0.62 Y Y S. haemolyticus N 39 1434
219 GPCc S. capitis 1.509 6 0.341 Yb WC S. haemolyticus Y MD MD
7 GPCc S. hominis 1.882 6 0.436 Y Y S. hominis N 92 1324
11 GPCc S. hominis 1.893 4 0.739 Y Y S. hominis N 65 1681
21 GPCc S. hominis 1.706 6 0.621 Y Y S. hominis N 273 1583
39 GPCc S. hominis 2.095 6 1.053 Y Y S. hominis N 134 1462
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validated cut-offs of 1.4 and 1.6 for the acceptable identiﬁca-
tion to the genus and species levels, respectively. A difference
of at least 0.3 between the ﬁrst identiﬁcation match and the
ﬁrst discrepant match was also required to validate the
identiﬁcation [14]. The last criterion was not required if the
identiﬁcation score value met the manufacturer’s instructions
(cut-off values of 1.7 and 2 for the acceptable identiﬁcation to
the genus and species levels, respectively). The RMIs that
showed a discrepancy with the Gram staining results were also
classiﬁed as unreliable.
Clinical impact evaluation
The design of the prospective analysis is presented in Fig. 1.
For each positive blood culture, the Gram staining result was
transmitted to the IDS, who answered in a blinded manner
several questions on the clinical presentation and current
antibiotic treatment of the patient and explained his thera-
peutic decision. All data were registered in a standardized case
report form by the medical microbiologist (see Supplementary
material, Fig. S1). When the RMI was transmitted, the IDS
informed the medical microbiologist of any modiﬁcation of his
initial therapeutic decision. All cases in which the RMI provided
another beneﬁt were also recorded. Indeed, RMIs from blood
cultures showing staphylococcal forms on the Gram staining
were expected to exclude or conﬁrm Staphylococcus
aureus infections, catheter-related infections and contami-
nations. The detection of particular organisms could also
indicate which additional medical investigations could be
conducted to determine the origin of the septic infection if it
was unknown.
A retrospective analysis of all cases was then performed.
For Saint-Pierre patients, the pharmacy department used
billing, medical and nursing ﬁles to retrospectively evaluate
whether the IDS’s therapeutic recommendations were fol-
lowed. The IDSs of both institutions also retrospectively
checked the medical ﬁles. In this section, the RMI/conventional
identiﬁcation delay, the IDS contact/adaptation of the treat-
ment delay (when needed) and the inﬂuence of the medical
Table 2 (Continued)
Patient
no.
Gram
staining RMI Score H Log
Reliable
RMI? T? CIT
RMI/CIT
discrepancy
From
incubator
removal to
RMI delay
(min)
From
incubator
removal to
CIT delay
(min)
72 GPCc S. hominis 1.78 5 0.78 Y Y S. hominis N 148 1440
73 GPCc S. hominis 1.84 6 0.833 Y Y S. hominis N 177 1439
113 GPCc S. hominis 2.27 6 0.85 Y Y S. hominis N 161 1485
122 GPCc S. hominis 2.119 6 0.81 Y Y S. hominis N 100 1510
143 GPCc S. hominis 2.128 5 0.8 Y Y S. hominis N 71 1596
207 GPCc S. hominis 2.211 6 0.868 Y Y S. hominis N 251 1346
212 GPCc S. hominis 1.838 3 0.682 Y Y S. hominis N 37 1473
248 GPCc S. hominis 2.229 6 1.004 Y Y S. hominis N 54 1563
293 GPCc S. hominis 2.192 6 0.854 Y Y S. hominis N 75 1171
305 GPCc S. hominis 2.069 6 0.99 Y Y S. hominis N 57 1138
124 GPCpch S. pneumoniae 1.09 2 0.09 N WC S. mitis/oralis Yd 51 3549
235 GPCpch S. salivarius 1.386 4 0.095 N WC S. mitis/oralis N 175 1804
1 GPCpch S. pneumoniae 1.924 7 0.729 Y WC S. pneumoniae N 30 1396
18 GPCpch S. pneumoniae 1.735 6 0.513 Y WC S. pneumoniae N 94 2933
42 GPCpch S. pneumoniae 1.453 3 0.358 Yb Y S. pneumoniae N 95 1021
50 GPCpch S. pneumoniae 2.13 7 0.79 Y WC S. pneumoniae N MD MD
105 GPCpch S. pneumoniae 1.822 4 0.346 Y WC S. pneumoniae N MD MD
120 GPCpch S. pneumoniae 1.719 6 0.477 Y WC S. pneumoniae N 73 1571
185 GPCpch S. pneumoniae 1.341 3 0.193 N WC S. pneumoniae N 186 1771
198 GPCpch S. pneumoniae 1.364 4 0.165 N WC S. pneumoniae N 87 1627
242 GPCpch S. pneumoniae 1.986 6 0.602 Y WC S. pneumoniae N 150 1528
65 GPCpch S. pyogenes 2.15 8 0.571 Y Y S. pyogenes N 66 1532
68 GPCpch S. pyogenes 1.896 8 0.635 Y Y S. pyogenes N 22 1146
165 GPCpch S. pyogenes 1.847 7 0.613 Y Y S. pyogenes N 71 1597
195 GPCpch S. pyogenes 2.006 6 0.637 Y Y S. pyogenes N 31 1157
246 GPCpch S. pyogenes 2.27 8 0.678 Y Y S. pyogenes N 70 1523
60 GPCc S. saprophyticus 1.761 6 0.631 Y Y S. saprophyticus N 197 1608
159 GPCpch S. thermophilus 2.097 6 0.67 Y Y S. thermophilus N MD MD
CIT, conventional identiﬁcation technique; GPR, Gram-positive rods; GPCc, Gram-positive cocci in clusters; GPCpch, Gram-positive cocci in pairs and chains; Y: yes, N: no, WC:
with caution; NA: not applicable; MD, missing or incomplete data; B. cereus, Bacillus cereus; B. licheniformis, Bacillus licheniformis; C. amycolatum, Corynebacterium amycolatum;
S. pettenkoferi, Staphylococcus pettenkoferi; E. canis, Enterococcus canis; E. durans, Enterococcus durans; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; L. crispatus,
Lactobacillus crispatus; M. luteus, Micrococcus luteus; K. sedentarius, Kytococcus sedentarius; S. agalactiae, Streptococcus agalactiae; S. anginosus, Streptococcus anginosus; S. aureus,
Staphylococcus aureus; S. capitis, Staphylococcus capitis; S. dysgalactiae, Streptococcus dysgalactiae; S. epidermidis, Staphylococcus epidermidis; S. hominis, Staphylococcus hominis;
S. gallolyticus, Streptococcus gallolyticus; S. haemolyticus, Staphylococcus haemolyticus; S. pneumoniae, Streptococcus pneumoniae; S. mitis, Streptococcus mitis; S. salivarius, Streptococcus
salivarius; S. pyogenes, Streptococcus pyogenes; S. saprophyticus, Staphylococcus saprophyticus; S. thermophilus, Streptococcus thermophilus.
Homogeneity: number of successive matches identical to the ﬁrst one; log: difference between the score of the ﬁrst match and the ﬁrst discrepancy.
aThe medical microbiologist suggested an ‘Enterococcus sp.’ Identiﬁcation.
bRMI reliable to the genus level.
cContamination by cutaneous ﬂora was not excluded.
dKnown limitation of the MALDI-TOF MS.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E568–E581
E572 Clinical Microbiology and Infection, Volume 19 Number 12, December 2013 CMI
unit where blood cultures were collected on the utility of the
RMI were also determined.
Statistical analysis
The times needed to obtain the RMI and conventional
identiﬁcation results were evaluated and compared using
non-parametric Mann–Whitney–Wilcoxon test. A Fisher’s
exact test was used to compare the proportion of RMIs that
led to an altered treatment at each institution.
We also used Fisher’s exact test to determine whether the
RMI had a higher or lower impact on particular patient
populations; a lower impact could be expected in medical units
where clinicians routinely monitor infectious diseases (e.g.
patients from intensive care units and sterile units).
Results
Rapid microbial identiﬁcations
During the study period, positive blood cultures from 243
patients were included, and 277 RMIs were performed (see
Supplementary material, Table S1).
Based on the cut-off criteria, 61.01% and 38.99% of RMIs
(169/277, 108/277) were classiﬁed as ‘reliable’ and ‘unreliable’,
respectively [14]. The medical microbiologist transmitted
71.12% of all RMIs (197/277) to the IDS. All of the bacterial
RMIs transmitted to the IDS are presented in Tables 1, 2 and 3
and in Fig. 2. An RMI suggesting a Candida krusei fungaemia was
TABLE 3. Rapid microbial identiﬁcations (RMIs) transmitted to the infectious disease specialist (IDS) for mixed cultures (n = 18)
Patient
nr
Gram
staining RMI Score H Log
Reliable
RMI? T? CIT
RMI/CIT
discrepancy?
From
incubator
removal
to RMI
delay
(min)
From
incubator
removal
to CIT
delay
(min)
302 GPCc S. hominis 1.251 1 0.008 N WC S. hominis
Streptococcus sp.
Acinetobacter sp.
Y, IR 135 1176
19 GPCpch
GNR
C. brakii 2.021 1 0.035 Y Y E. faecalis
C. brakii
P. aeruginosa
Y, IR 270 2902
20 GNR
GPCpch
E. faecalis 2.257 8 0.897 Y Y E. coli
E. faecalis
S. aureus
Y, IR 273 1599
40 GPCc S. hominis 1.969 6 0.783 Y Y S. epidermidis
S. hominis
Y, IR 46 1629
44 GPCpch
GNR
E. faecalis
C. freundii
2.22
2.13
8
5
0.693
0.292
Y Y E. faecalis
C. freundii
Na 147 1534
46 GPCc S. epidermidis 1.767 6 0.639 Y Y S. epidermidis
S. epidermidis
N 119 1532
101 GNR
GPCpch
E. coli 2.162 8 0.366 Y Y E. coli
S. mitis/oralis
Y, IR 94 3115
137 GPCc S. capitis 1.727 4 0.586 Y Y S. capitis
S. haemolyticus
S. epidermidis
Y, IR MD MD
138 GNRcc H. inﬂuenzae 2.071 10 NA Y Y H. inﬂuenzae
K. pneumoniae
Y, IR 136 5853
152 GNR K. pneumoniae 2.078 3 0.325 Y Y K. pneumoniae
E. coli
Y, IR 59 1206
176 GNR E. coli 2.109 10 NA Y Y E. coli
K. pneumoniae
Y, IR 98 1556
177 GNR
GPR
K. pneumoniae 2.277 6 0.407 Y Y K. pneumoniae
L. lactis
Y, IR 97 1555
188 GNR E. coli 2.027 10 NA Y Y E. coli
E. coli
N 215 1510
189 GPCc
GPCpch
S. aureus 2.185 10 NA Y Y S. aureus
Streptococcus sp.
Y, IR 217 3146
193 GPCc
GPCpch
S. haemolyticus 1.919 7 0.502 Y Y S. haemolyticus
E. avium
Y, IR 487 1498
236 GPR
GNR
C. perfringensb
E. coli
1.872
1.738
Alternate ID NA Y Y C. perfringens
E. coli
S. salivarius
Y, IR 175 1578
261 GNR S. maltophilia 2.065 2 0.298 Y Y S. maltophilia
Ochrobactrum sp.
Y, IR 115 1415
279 GNR
GPCpch
M. morganii 2.492 10 NA Y Y M. morganii
E. faecalis
Y, IR 123 1583
CIT, conventional identiﬁcation technique; GNR, Gram-negative rods; GNRcc, Gram-negative rods coccobacilli; GPR, Gram-positive rods; GPCc, Gram-positive cocci in clusters;
GPCpch, Gram-positive cocci in pairs and chains; Y, yes; N, no; WC, with caution; NA, not applicable; IR, incomplete result.
C. brakii, Citrobacter brakii; C. freundi, Citrobacter freundi; C. perfringens, Clostridium perfringens; E. coli, Escherichia coli; E. faecalis, Enterococcus faecalis; H. inﬂuenzae, Haemophilus
inﬂuenzae; K. pneumoniae, Klebsiella pneumoniae; L. lactis, Lactococcus lactis; M. morganii, Morganella morganii; P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus;
S. capitis, Staphylococcus capitis; S. epidermidis, Staphylococcus epidermidis; S. haemolyticus, Staphylococcus haemolyticus; S. hominis, Staphylococcus hominis; S. maltophila, Stenotroph-
omonas altophilia; S. mitis, Streptococcus mitis.
Homogeneity: number of successive matches identical to the ﬁrst one; log: difference between the score of the ﬁrst match and the ﬁrst discrepancy.
aRMI was performed on two positive blood culture bottles for this patient.
bBoth identiﬁcations appeared alternatively in the ten matches, with acceptable score values.
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TABLE 4. Clinical context and description of cases for whom the Gram result led to a modiﬁcation of the empirical antimicrobial
treatment (n = 34)
N°
Gram
staining RMI result CIT
Current
antibiotic
treatment
Clinical
context
Treatment
modiﬁcation
according to
the IDS survey Comment
Saint-Pierre University Hospital
Adults
119 GNR Proteus mirabilis P. mirabilis 0 Septic shock <UTI AMC addition Community acquired UTI
98 GPCc Staphylococcus
aureus
S. aureus 0 Dyspnoea, dialysis Vancomycin
addition
Suspicion of CNS infection
in a patient with multiple
or permanent catheters
38 GNR Escherichia coli E. coli AMC Pyelonephritis Shift to temocillin Hospital acquired
pyelonephritis
44 GPCpch+GNR Enterococcus
faecalis
Citrobacter
freundii
E. faecalis
C. freundii
PTZ Shock of
unknown origin
Vancomycin and
metronidazole
addition
To cover E. faecium and
Bacteroides sp.
258 GNR E. coli E. coli 0 UTI Temocillin
addition
E. coli previously found in
urine sample
273 GNR E. coli E. coli Levoﬂoxacin
+ oxacillin
Mediastinitis
post cardiac
surgery + UTI
Shift to PTZ Hospital acquired infection,
broader antimicrobial
spectrum
214 GNR E. coli E. coli AMC Septic shock,
angiocholitis
Shift to PTZ Severe infection, broader
antimicrobial spectrum
97 GNR
Campylobacter
suspected
Campylobacter
fetus
Campylobacter sp. PTZ Diarrhoea Shift to
clarithromycin
According to guidelines
106 GPCc CNS CNS AMC Pulmonary infection Shift to PTZ Treatment modiﬁcation
probably explained by the
clinical context more than
the Gram result
211 GNR Klebsiella
pneumoniae
K. pneumoniae 0 Septic shock,
brain tumour
PTZ addition Hospital acquired infection,
broad antimicrobial spectrum
42 GPCpch Streptococcus
pneumoniae
S. pneumoniae 0 Pulmonary infection AMC addition S. pneumoniae highly
suspected
55 GNR Salmonella sp. S. paratyphi 0 Salmonellosis Levoﬂoxacin
addition
Salmonella highly suspected,
according to guidelines
Paediatrics
150 GNR Salmonella sp. Salmonella sp. 0 Diarrhoea, fever
and nausea
Ceftriaxon
addition
Salmonella highly suspected,
according to guidelines
(for paediatric patient)
159 GPCpch Streptococcus
thermophilus
S. thermophilus Ampicillin
+ cefotaxime
Bronchiolitis, fever Stop ampicillin Pulmonary origin suspected
246 GPCpch Streptococcus
pyogenes
S. pyogenes Temocillin UTI Shift to
cefotaxim
Pulmonary origin suspected
45 GNR E. coli E. coli Ampicillin
+ cefotaxime
UTI Stop ampicillin Because of the high ampicillin
resistance in GNR
120 GPCpch S. pneumoniae S. pneumoniae AMC Suspicion of
ethmoiditis
Shift to intravenous
administration
According to guidelines
Jules Bordet Institute
96 GPCc Staphylococcus
epidermidis
S. epidermidis 0 Lymphoma Vancomycin
addition
Suspicion of CNS infection
in a patient with a
permanent catheter
180 GPCpch E. faecalis E. faecalis Temocillin Endometrial cancer,
pyelonephritis, fever
PTZ addition Genital origin suspected,
broader antimicrobial
spectrum
197 GPCpch E. faecalis E. faecalis 0 Abdominal surgery PTZ and
vancomycin
addition
Abdominal origin suspected,
broad antimicrobial spectrum
161 GPCc S. epidermidis S. epidermidis Cefepim Acute leukaemia,
neutropenia
Vancomycin
addition
Suspicion of CNS infection
in a patient with multiple
or permanent catheters
267 GPCc S. epidermidis S. epidermidis 0 Medullary graft,
Systematic blood
culture collection
for patients receiving
high doses
of corticosteroids
Vancomycin
addition
Suspicion of CNS infection
in a patient with multiple
or permanent catheters
261 GNR Stenotrophomonas
maltophilia
S. maltophilia
+ Ochrobactrum sp.
0 Intestinal disease PTZ addition Abdominal origin suspected,
broad antimicrobial spectrum
262 GNR Enterobacter
cloacae
E. cloacae 0 Cholangiocarcinoma PTZ addition Abdominal origin suspected,
broad antimicrobial spectrum
250 GNR E. coli E. coli Meropenem Septic shock <UTI Shift to PTZ E. coli susceptible to PTZ
previously found in clinical
samples
215 GPCpch Streptococcus
anginosus
S. anginosus Oxacillin Earn, Nose and
Throat neoplasy
Shift to
moxiﬂoxacin
Better cellular penetration
184 GPCc Kytococcus
sedentarius
Micrococcus sp. Meropenem Acute leukaemia,
neutropenia, fever
Vancomycin
addition
Suspicion of CNS infection
in a patient with multiple
or permanent catheters
189 GPCc+GPCpch S. aureus S. aureus
Streptococcus sp.
TZP Neutropenia, fever Vancomycin
addition
Suspicion of CNS infection
in a patient with multiple
or permanent catheters
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also transmitted to the IDS, with caution because of a poor
score value (see Table S1, patient no. 174).
The RMIs that were not transmitted (28.88%, 80/277)
included ﬁve reliable RMIs that were erroneously not trans-
mitted by the medical microbiologist (oversight) and 75
unreliable RMIs.
Among the unreliable RMIs, 30.56% were nevertheless
transmitted to the IDS, with caution (33/108; Fig. 2). These
RMIs showed high levels of homogeneity in the ten identiﬁ-
cation matches, had good score values but failed to meet the
0.3 log difference criterion (a difference of at least 0.3 between
the best match and the ﬁrst discrepant match was required) or
were partially informative (genus information or suspicion of
‘coagulase-negative’ Staphylococcus). The decision to transmit
data based on unreliable RMIs was made by the medical
microbiologist according to his experience.
Among the 197 transmitted RMIs (164 + 33), 88.32% were
conﬁrmed by the culture-based identiﬁcation methods (174/
197), 4.06% (8/197) showed erroneous identiﬁcations (six
RMIs transmitted with caution, one Acinetobacter sp.—RMI no.
90—and one Staphylococcus epidermidis identiﬁed as Staphylo-
coccus hominis that most likely resulted from contamination
with cutaneous ﬂora). The remaining 7.61% (15/197) were
RMIs based on mixed cultures; for eight of them, the Gram
staining suggested the presence of several organisms, and for
all of them, at least one microorganism remained undetected
using the RMI technique. The RMIs for the mixed cultures are
presented in Table 3.
Prospective analysis
The transmitted RMIs corresponded to 40 paediatric and 90
adult patients from Saint-Pierre and 67 patients from Jules
Bordet. The survey showed that the Gram staining results led
to a modiﬁcation of the patient’s treatment in 17.26% of cases
(34/197, see Table 4).
All clinical data for patients who beneﬁted from the RMIs
according to our survey (conﬁrmation of contamination
excluded, n = 29) are presented in Table 5.
Of the adult patients, the RMIs led to a modiﬁcation of the
empirical treatment in 11.11% (10/90) and 14.93% (10/67) of
cases according to the IDSs of Saint-Pierre and Jules Bordet,
respectively (p 0.48).
For adult patients at Saint-Pierre, the modiﬁcation of the
empirical treatment consisted of the addition of a new drug in
80% (8/10). At Jules Bordet, the RMIs led to the addition of a
new drug in only 20% of cases (2/10), the cessation of
treatment in 20% of cases (2/10) and changes in the
antimicrobial treatment regimen in 30% of cases (3/10); in
addition, the RMIs prevented the initiation of useless treat-
ments in 30% of cases at this institution (3/10).
In the paediatric population, the IDSs reported a modiﬁca-
tion of the empirical treatment (escalation) in only 2.50% of
cases (1/40).
According to the survey, 37.5% of the RMIs (15/40) for the
paediatric population allowed for the rapid conﬁrmation of
contamination. In 73.3% of those RMIs (11/15), the RMI
highlighted the presence of a coagulase-negative Staphylococcus
but a blood infection was excluded in all cases because blood
cultures were collected at the paediatric emergency depart-
ment and none of these patients had either catheters or other
medical devices. The RMI conﬁrmed contamination for only
11.11% (10/90) and 5.97% (4/67) of adult patients from
Saint-Pierre and Jules Bordet, respectively (see Supplementary
material, Table S2). The conﬁrmation of contaminated sam-
ples never led to the modiﬁcation of the antimicrobial
treatment.
Table 4 (Continued)
N°
Gram
staining RMI result CIT
Current
antibiotic
treatment
Clinical
context
Treatment
modiﬁcation
according to
the IDS survey Comment
41 GNR K. pneumoniae K. pneumoniae 0 Ear, Nose and
Throat neoplasy
PTZ and amikacin
addition
P. aeruginosa was suspected
in an infected wound
146 GPCc S. epidermidis S. epidermidis 0 Systematic blood culture
collection for patients
receiving high doses
of corticosteroids
Vancomycin
addition
Suspicion of CNS infection in
a patient with multiple or
permanent catheters
101 GNR+GPCc E. coli E. coli
Streptococcus
mitis/oralis
Cefepim Acute leukaemia,
neutropenia
Vancomycin
addition
Suspicion of CNS infection in
a patient with multiple or
permanent catheters
90 GNR Acinetobacter
genomospecies
Acinetobacter lowﬁi AMC Hepatic disease, fever PTZ+amikacin Because of the high AMC
resistance in GNR
70 GNR E. coli E. coli 0 Acute leukaemia,
septic shock
Meropenem
addition
Hospital acquired infection in
a patient in sterile unit
73 GPCc Staphylococcus
hominis
S. hominis 0 MD Vancomycin
addition
Suspicion of CNS infection in
a patient with multiple or
permanent catheters
CIT, conventional identiﬁcation technique; CNS, central nervous system; PTZ, piperacillin/azobactam; AMC, amoxicillin/clavulanic acid; IDS, infectious disease specialist.
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C?, compliance with IDS recommendations (according to the IDS retrospective analysis)?;  Y, yes; N, no; MD, missing or incomplete data; NA, not applicable; ND, not done;
CRP, C-reactive protein; MRSA, methicillin resistant Staphylococcus aureus;  VRE, vancomycin resistant Enterococcus;  COPD, chronic obstructive pulmonary disease; PTZ,  piperacillin/tazobactam; AMC,  amoxicillin/clavulanic acid;  CVC,  central venous catheter.
* The medical microbiologist told the IDS that an anaerobic bacteria was suspected,
**Adaptation was done before getting the identification by conventional methods but the precise administration time is unknown (after 3 days for patient 56). 
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For adult patients, the IDSs reported other beneﬁts of RMI
for 4.44% and 7.46% of patients at Saint-Pierre and Jules
Bordet, respectively. Such beneﬁts included requests for new
blood cultures (n = 2), removal or control of catheters
(n = 4), additional medical investigations (n = 3) and resolving
confusion over the samples of two patients (n = 1); as
presented in Table 5.
Retrospective analysis
Compliance with IDS recommendations, according to the IDS
and pharmacy data, is presented in Table 5.
For recommendations regarding the patients at Saint-Pierre
(n = 15), the pharmacy data suggested that the recommended
treatment adaptations were implemented in 9/10 cases before
the results of the conventional methods were available. Several
discrepancies were observed between the IDS and pharmacy
data that may be partially explained by the lack of information
in the billing, medical and nursing ﬁles.
The IDSs also highlighted an eleventh case not detected by
the survey in which the RMI led to the rapid adaptation of the
treatment regimen.
For recommendations regarding the patients at Jules Bordet
(n = 14), with the exception of one patient, the IDS conﬁrmed
that all recommendations were respected and that all treat-
ment modiﬁcations were implemented the same day as the
RMI results became available.
The median times required to obtain an identiﬁcation result
from both the RMI and the conventional methods were
evaluated using 178 of the 197 transmitted RMIs (19 were
excluded because of missing data) and found to be 1 h 35 min
(95 min; minimum–maximum: 15–596 min) and 25 h 43 min
(1543 min, 1021–10499 min), respectively. This difference was
statistically signiﬁcant (p <0.001) (see Supplementary material,
Table S3).
The delay between the transmission of the RMI to the IDS
and the administration of the modiﬁed treatment was >4 h in
50% of the cases (4/8, two incomplete or missing data, Table 5).
The Fisher’s exact test showed no signiﬁcant difference in
the impact of the RMI according to the medical unit where the
samples were collected (see Supplementary material, Fig. S2).
Discussion
MALDI-TOF MS has emerged as a promising tool for the rapid
identiﬁcation of organisms from positive blood cultures [13–
15]. Numerous strategies were evaluated to optimize RMI
from positive blood cultures. A previous evaluation showed
that our RMI protocol was able to correctly identify 73.7% of
the blood culture bacteria at the species level in <1 h [14]. The
inclusion of a higher proportion of Gram-positive bacteria that
are usually less successfully identiﬁed by MALDI-TOF MS RMI
techniques may explain the lower rate of successful identiﬁ-
cations observed in the present study (61.01% vs 73.7%).
To date, the clinical impact of this type of RMI has been
poorly investigated [16].
The major strength of our study is the prospective
collection of data that led to similar observations for two
medical institutions treating different patient populations.
Our results suggest that MALDI-TOF MS may hasten the
modiﬁcation of empirical treatment regimens in 13.38% of
cases in the adult population (21/157). The same proportion
of treatment regimens were altered (p 0.64) at both
Saint-Pierre (11/90, 12.22%, including the eleventh case, which
was highlighted during the retrospective analysis) and Jules
Bordet (10/67, 14.93%). A recent study by Stoneking et al.
[18] that retrospectively evaluated the effect of more rapid
microorganism identiﬁcation in bacteraemic emergency
department patients suggests that the empirical therapy would
remain unchanged in only 23% of cases; the remaining 21.3%
and 55.7% of patients would receive treatment with an
additional antibiotic for organisms not covered by the initial
regimen or the adjustment of the regimen to reduce the
spectrum of the antibiotics, respectively. Applying the same
analysis (excluding contaminated blood cultures and missing
data) to adult patients at Saint-Pierre, 78.95% of treatments
would remain unchanged. In our study, the proportion of
patients who were infected with pathogens not affected by the
initial antibiotic regimen was in agreement with the number
reported by Heenen et al. [19] in their study of de-escalation
in a medico-surgical intensive care unit (16%). We ﬁrst
thought that the high rate of unchanged treatments in our
study could be explained by the fact that two-thirds of the
patients were hospitalized and received treatment that was
based on previous positive samples other than blood cultures.
However, the medical unit where the blood cultures were
collected did not seem to affect the proportion of treatment
modiﬁcations in our study. The difference may therefore be
explained by the implementation of antimicrobial stewardship
programmes in both the Saint-Pierre and Jules Bordet medical
centres.
In the Jules Bordet patient population, most modiﬁcations of
the antimicrobial treatment regimens due to the RMI involved
de-escalation. In contrast, most modiﬁcations at Saint-Pierre
involved treatment escalation. This difference can most likely
be explained by the speciﬁc population of the Jules Bordet
facility, which manages only cancer patients. For such patients,
IDSs are confronted with known clinical presentations and
must follow rational schemes. Broad-spectrum antibiotics are
also most likely to be used in this population.
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In both medical centres, the RMI of Enterococcus species and
b-hemolytic streptococci was responsible for 30% of the
modiﬁcations of the antimicrobial treatment, which suggests
that performing RMI on positive blood cultures showing
Gram-positive cocci in pairs or chains may be of interest
despite the known limitations of the MALDI-TOF MS
technique (no discrimination of Streptococcus mitis/oralis from
Streptococcus pneumoniae).
In the oncological population, the conﬁrmation/exclusion of
non-fermenting Gram-negative rod involvement was also
responsible for 30% of the observed modiﬁcations in the
antimicrobial treatment, conﬁrming the previous results of
Clerc et al. [20], who highlighted the great beneﬁt of the RMI
on the clinical management of patients infected with
Gram-negative bacteria.
For paediatric patients, MALDI-TOF MS was especially
useful for the rapid conﬁrmation of contaminated blood
cultures (37.5%). However, these observations never led to a
de-escalation of the antimicrobial treatment. As previously
suggested, failure to follow the IDSs’ recommendations may be
a result of physicians’ reluctance to modify treatment in
patients who are improving [3].
In our study, most changes to the treatment regimen were
made before the genus and/or species identiﬁcation results
provided by the conventional methods were available. This
high level of compliance certainly results from the design of the
study; telephone calls, which allow for a two-way exchange,
considerably improved the communication between microbi-
ologists and IDSs [3]. Additionally, it is well known that the
implementation of multidisciplinary teams is of major impor-
tance for the optimization of antibiotic therapy in clinical
settings [21]. However, the delay for the administration of a
modiﬁed treatment was high (>4 h in 50% of cases), and the
communication between other health professionals involved in
the antimicrobial treatment administration process (clinicians,
nurses, pharmacists) should therefore be improved in our
institution. Major improvements of our electronic prescribing
system and of the delivery of urgent antimicrobial agents are
also awaited. This point will be addressed to our antimicrobial
stewardship team members who are particularly skilful at
improving such processes.
With a decrease of 26.85 h in the time required for
identiﬁcation and a 13.38% increase in the proportion of patients
receiving an appropriate antimicrobial treatment 24 h after the
positive blood culture, our results are in perfect agreement with
those presented in the recent publication of Vlek et al. [22]
(28.8 h, 11.3%). The major difference between their study and
the present study is the study design: Vlek et al. compared a
‘standard care’ group with an ‘intervention’ group, whereas we
opted for a blinded prospective analysis of a single patient group.
Although it may not always lead to the modiﬁcation of the
treatment regimen, RMI plays an important—and unfortu-
nately difﬁcult to quantify—role in the global management of
the patient. The conﬁrmation of a contaminant is of particular
interest for non-hospitalized patients and can help to avoid the
administration of unnecessary antibiotics. On the other hand,
the conﬁrmation of a catheter-related infection—usually made
by ‘time-to-positivity’ determination—will allow for the rapid
removal of infected devices and can help to prevent further
infections. The detection of particular organisms may also
allow the clinician to identify the origin of the sepsis and
therefore contribute to cost-saving measures.
From a ﬁnancial point of view, performing RMI requires an
additional cost, primarily because of the need for additional
staff and an adapted workﬂow. In addition, the use of
conventional identiﬁcation methods is still needed to resolve
cases of mixed cultures or unreliable RMIs.
Because of these practical considerations and because a
case-by-case selection of which RMI to perform in collaboration
with the IDSwould probably slow down the analytical workﬂow,
we decided to perform the analysis only twice daily, which seems
to be the most efﬁcient option for our laboratory. The
optimization of the technique, including automation, should
lessen the ﬁnancial impact of the technique in the future.
Our study has several limitations. First, the analysis of the
pharmacy data highlighted the difﬁculty in identifying accurate
indicators and revealed discrepancies between the billing,
medical and nursing ﬁles. At our institution, improvements in
computerization in the near future will most likely improve
data handling [23]. Second, the observations presented in this
study are only valid for similar organizations. Indeed, a higher
clinical impact might be observed in institutions where the
laboratory and pharmacy are open 24 h per day and an IDS is
on site at all times. Both Saint-Pierre and Jules Bordet have
antimicrobial stewardship programmes and numerous IDSs.
These factors might explain a high rate of appropriate
empirical treatment and the rapid adaptation of antimicrobial
therapies because of frequent re-evaluations. Medical institu-
tions without IDSs would most likely receive a greater beneﬁt
from RMI. The beneﬁt of the RMI could also be different in
institutions dealing with a high proportion of antimicro-
bial-resistant bacteria (e.g. methicillin-resistant S. aureus or
extended spectrum b-lactamase producers), which is currently
not the case in our hospitals.
Conclusion
In an adult population, 13.38% of theMALDI-TOFMSRMIs from
positive blood cultures resulted in the faster adaptation of the
ª2013 The Authors
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antimicrobial treatment regimen. The technique is also able to
rapidly conﬁrm contamination, especially in the paediatric
population (37.5%), and is able to hasten the removal of infected
catheters and suggest complementary diagnostic investigations.
Despite the increased cost for the laboratory, RMI analyses are
routinely performed twice daily in our laboratory. However, the
use of RMI should not be considered unless there is efﬁcient
communication between health professionals.
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